Drug Profile
Research programme: sirtuin targeted therapeutics for respiratory viral infections - Evrys Bio
Latest Information Update: 16 Jul 2021
Price :
$50
*
At a glance
- Originator FORGE Life Science; Princeton University
- Developer Evrys Bio
- Class Antivirals; Small molecules
- Mechanism of Action Sirtuin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections; Influenza virus infections; Respiratory syncytial virus infections
Most Recent Events
- 13 Jul 2021 Preclinical trials in Respiratory syncytial virus infections, Influenza virus infections is ongoing in USA (PO)
- 13 Jul 2021 Preclinical trials in COVID-2019 infections in USA (PO)
- 13 Jul 2021 Preclinical trials in Influenza virus infections in USA (PO)